Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 1 - 20 results of 5,361 for search '(( _ large decrease ) OR ((( _ largest decrease ) OR ( 5 ((teer decrease) OR (mean decrease)) ))))', query time: 0.53s Refine Results
  1. 1
    Decadal mean regional hydrology.

    Decadal mean regional hydrology. by Nic Gedney (19762301)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 2
    Contemporary mean inundation fraction in the Amazon basin.

    Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 3
    Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin.

    Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. by Nic Gedney (19762301)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 4
    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells.

    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  5. 5
    NSC population and proliferation decrease drastically during the second postnatal week of DG development.

    NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  7. 7
    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells.

    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  8. 8
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  9. 9
    Innovation and night light in large and small cities.

    Innovation and night light in large and small cities. by Saul Estrin (8629173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 10
    Geographical distribution of large cities and small cities.

    Geographical distribution of large cities and small cities. by Saul Estrin (8629173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: